Is Withaferin A, a magic bullet for metabolic syndrome?

Biomedicine and Pharmacotherapy

Volumn 92, Issue , 2017, Pages 1135-1137

  Santhekadur, Prasanna K ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELASTROL; GLUCOSE; LEPTIN; WITHAFERIN A; PHYTOSTEROL; WITHANOLIDE;

ENDOPLASMIC RETICULUM STRESS; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN TOLERANCE TEST; LETTER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; WITHANIA;

HUMANS; METABOLIC SYNDROME; PHYTOSTEROLS; WITHANIA; WITHANOLIDES;

EID: 85017447040     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.04.002     Document Type: Letter

References (48)

1. Lee, J., Liu, J., Feng, X., et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat. Med. 22 (2016), 1023–1032.
2. Piao, L., Canguo, Z., Wenjie, L., et al. Lipopolysaccharides-stimulated macrophage products enhance Withaferin A-induced apoptosis via activation of caspases and inhibition of NF-κB pathway in human cancer cells. Mol. Immunol. 81 (2017), 92–101.
3. Ven Murthy, M.R., Ranjekar, P.K., Ramassamy, C., Deshpande, M., Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: Ashwagandha. Cent. Nerv. Syst. Agents Med. Chem. 10 (2010), 238–246.
4. Singh, N., Bhalla, M., de Jager, P., Gilca, M., An overview on Ashwagandha: a Rasayana (rejuvenator) of ayurveda. Afr. J. Tradit. Complement. Altern. Med. 8 (2011), 208–213.
5. Charaka, Charak Samhita 6000BC, Translation into English: Translator: Shree Gulabkunverba. 1949, Ayurvedic Society, Jamnagar, India.
6. Mishra, L.C., Singh, B.B., Dagenais, S., Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern. Med. Rev. 5 (2000), 334–346.
7. Winters, M., Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern. Med. Rev. 11 (2006), 269–277.
8. G.S. Sharma, Ashwagandharishta – Rastantra Sar Evam Sidhyaprayog Sangrah –Krishna-Gopal Ayurveda Bhawan (Dharmarth Trust), Nagpur, (1938), 743–744.
9. P.V. Sharma, Ashwagandha, Dravyaguna Vijana, Chaukhambha Viashwabharti Varanasi. (1999) 763–765.
10. Tiwari, R., Chakraborty, S., Saminathan, M., Dhama, K., Singh, S.V., Ashwagandha (Withania somnifera): role in safeguarding health, immunomodulatory effects, combating infections and therapeutic applications: a review. J. Biol. Sci. 14 (2014), 77–94.
11. Mishra, B.B., Tiwari, V.K., Natural products: an evolving role in future drug discovery. Eur. J. Med. Chem. 46 (2011), 4769–4807.
12. Ji, H.F., Li, X.J., Zhang, H.Y., Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?. EMBO Rep. 10 (2009), 194–200.
13. Beutler, J.A., Natural products as a foundation for drug discovery. Curr. Protoc. Pharmacol. 46 (2009), 1–9.
14. Gupta, P., Goel, R., Agarwal, A.V., Asif, M.H., Sangwan, N.S., Sangwan, R.S., Kumar Trivedi, P., Comparative transcriptome analysis of different chemotypes elucidates withanolide biosynthesis pathway from medicinal plant Withania somnifera. Sci. Rep. 5 (2015), 18611–18624.
15. Kataria, H., Shah, N., Kaul, S.C., Wadhwa, R., Kaur, G., Water extract of ashwagandha leaves limits proliferation and migration, and induces differentiation in glioma cells. Evid. Based Complement. Altern. Med. 2011 (2011), 1–12.
16. Yadav, B., Bajaj, A., Saxena, M., Saxena, A.K., In vitro anticancer activity of the root, stem and leaves of Withania somnifera against various human cancer cell lines. Indian J. Pharm. Sci. 72 (2010), 659–663.
17. Khare, C.P., Botany 1 st edition Indian Herbal Remedies: Rational Western Therapy, Ayurvedic and Other Traditional Usage, 1, 2004, Springer Science & Business Media, 479–484.
18. Singh, G., Sharma, P.K., Dudhe, R., Singh, S., Biological activities of Withania somnifera. Ann. Biol. Res. 1 (2010), 56–63.
19. Sitansu, K.V., Ajay, K., Therapeutic uses of Withania Somnifera (Ahwagandha) with a note on Withanalides and its pharmacological actions. Asian J. Pharm. Clin. Res. 4 (2011), 1–4.
20. Uddin, Q., Samiulla, L., Singh, V.K., Jamil, S.S., Phytochemical and pharmacological profile of withania somnifera dunal: a review. J. Appl. Pharm. Sci. 2 (2012), 170–175.
21. Lee, I.C., Choi, B.Y., Withaferin-A-a natural anticancer agent with pleitropic mechanisms of action. Int. J. Mol. Sci. 17 (2016), 1–22.
22. Vyas, A.R., Singh, S.V., Molecular targets and mechanisms of cancer prevention and treatment by withaferin A, a naturally occurring steroidal lactone. AAPS J. 16 (2014), 1–10.
23. Berghe, W.V., Sabbe, L., Kaileh, M., Haegeman, G., Heyninck, K., Molecular insight in the multifunctional activities of Withaferin A. Biochem. Pharmacol. 84 (2012), 1282–1291.
24. Grin, B., Mahammad, S., Wedig, T., Cleland, M.M., Tsai, L., Herrmann, H., Goldman, R.D., A alters intermediate filament organization, cell shape and behavior. PLoS One, 7, 2012, e39065.
25. Lee, J., Hahm, E.R., Singh, S.V., Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells. Carcinogenesis 31 (2010), 1991–1998.
26. Prasanna Kumar, S., Shilpa, P., Salimath, B.P., Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor. Curr. Trends Biotechnol. Pharm. 3 (2009), 138–148.
27. Mohan, R., Hammers, H.J., Bargagna, M.P., Zhan, X.H., Herbstritt, C.J., et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7 (2004), 115–122.
28. Bargagna, M.P., Ravindranath, P.P., Mohan, R., Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 47 (2006), 4138–4145.
29. Kakar, S.S., Worth, C.A., Wang, Z., Carter, K., Ratajczak, M., Gunjal, P., DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer. J. Cancer Stem Cell Res., 4, 2016, e1002.
30. Suman, S., Das, T.P., Moselhy, J., et al. Oral administration of withaferin A inhibits carcinogenesis of prostate in TRAMP model. Oncotarget 7 (2016), 53751–53761.
31. Samanta, S.K., Sehrawat, A., Kim, S.H., et al. Disease subtype-independent biomarkers of breast cancer chemoprevention by the ayurvedic medicine phytochemical Withaferin A. J. Natl. Cancer Inst. 109 (2016), 1–13.
32. Liu, X., Qi, W., Cooke, L.S., et al. An analog of withaferin A activates the MAPK and glutathione stress pathways and inhibits pancreatic cancer cell proliferation. Cancer Invest. 29 (2011), 668–675.
33. Choi, B.Y., Kim, B.W., Withaferin-A inhibits colon cancer cell growth by blocking STAT3 transcriptional activity. J. Cancer Prev. 20 (2015), 185–192.
34. Li, W., Zhang, C., Du, H., et al. Withaferin A suppresses the up-regulation of acetyl-coA carboxylase 1 and skin tumor formation in a skin carcinogenesis mouse model. Mol. Carcinog. 55 (2016), 1739–1746.
35. Vedi, M., Sabina, E.P., Assessment of hepatoprotective and nephroprotective potential of withaferin A on bromobenzene-induced injury in Swiss albino mice: possible involvement of mitochondrial dysfunction and inflammation. Cell Biol. Toxicol. 32 (2016), 373–390.
36. Jadeja, R.N., Urrunaga, N.H., Dash, S., et al. Withaferin-A reduces acetaminophen-induced liver injury in mice. Biochem. Pharmacol. 97 (2015), 122–132.
37. Dave, V.P., Kaul, D., Sharma, Y., Bhattacharya, R., Functional genomics of blood cellular LXR-alpha gene in human coronary heart disease. J. Mol. Cell. Cardiol. 46 (2009), 536–544.
38. Mehrotra, A., Kaul, D., Joshi, K., LXR-α selectively reprograms cancer cells to enter into apoptosis. Mol. Cell. Biochem. 349 (2011), 41–55.
39. Joseph, S.B., Castrillo, A., Laffitte, B.A., Mangelsdorf, D.J., Tontonoz, P., Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003), 213–219.
40. Repa, J.J., Liang, G., Ou, J., et al. Regulation of mouse sterol regulatory element- binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXR alpha and LXR beta. Genes Dev. 14 (2000), 2819–2830.
41. Higuchi, N., Kato, M., Shundo, Y., et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38 (2008), 1122–1129.
42. Pfluger, P.T., Tschöp, M.H., Obesity: will withaferin win the war?. Nat. Med. 22 (2016), 970–971.
43. Ravindran, R., Sharma, N., Roy, S., et al. Interaction studies of withania somnifera's key metabolite withaferin a with different receptors associated with cardiovascular disease. Curr. Comput. Aided Drug Des. 11 (2015), 212–221.
44. Challa, A.A., Vukmirovic, M., Blackmon, J., Stefanovic, B., Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo. PLoS One, 7, 2012, e42989.
45. Friedman, J.M., Modern science versus the stigma of obesity. Nat. Med. 10 (2004), 563–569.
46. Frederich, R.C., Hamann, A., Anderson, S., et al. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 12 (1995), 1311–1314.
47. Friedman, J.M., A tale of two hormones. Nat. Med. 16 (2010), 1100–1106.
48. Liu, J., Lee, J., Salazar Hernandez, M.A., Mazitschek, R., Ozcan, U., Treatment of obesity with celastrol. Cell 161 (2015), 999–1011.